Elderly Cancer Populations Have Inconsistent Symptom Burden/Clusters
Lack of energy, difficulty with sleeping, and pain were some of the most common symptoms reported in older patients with cancer.
ASCO Guideline Issues Updated Systemic Therapy Recommendations in HCC
Data from 10 new randomized clinical trials support updated recommendations for various systemic therapy regimens in hepatocellular carcinoma.
Defining a Nurse Coordinator’s Role During Outpatient CAR T-Cell Therapy
One of the most important roles of a nurse coordinator is transmitting patient and caregiver information during the CAR T-cell treatment process.
Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma
Researchers from MSKCC have explored the potential of personalized fludarabine dosing, based on population pharmacokinetics, to enhance the outcomes of CD19 CAR T-cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphomas.
Early inflammatory markers as prognostic indicators following allogeneic stem cell transplantation
Researchers at the University of Birmingham in the UK have explored the dynamics of inflammatory biomarkers following allogeneic hematopoietic stem cell transplantation.
New Tocilizumab Workflow Is More Effective for CRS Related to CAR T, Bispecific Antibodies
A verbal tocilizumab workflow helped provide safer and more effective delivery of the agent for patients experiencing cytokine release syndrome.
Loncastuximab Tesirine Combo Is Effective, Safe in R/R Follicular Lymphoma
Loncastuximab tesirine and rituximab led to encouraging responses in most patients with relapsed/refractory follicular lymphoma in a single-center study.
Cilta-cel Yields Sustained Responses in R/R Multiple Myeloma
Findings from the CARTITUDE-2 trial support the use of cilta-cel in patients with multiple myeloma, says Tina Glow, AAS, RN, BSN.
Cilta-cel Shows High Responses for Lenalidomide-Refractory Myeloma in First Relapse
The latest CARTITUDE-4 data examine the efficacy and safety of ciltacabtagene autoleucel in lenalidomide-refractory multiple myeloma.
Cranial Nerve Palsy Present Across CARTITUDE Trials in Multiple Myeloma
Patients enrolled across the CARTITUDE trials who experienced cranial nerve palsy after treatment with cilta-cel were generally male.
Eftilagimod Alpha/Pembrolizumab Elicits Encouraging Responses in HNSCC
The phase 2b findings support the capability of eftilagimod alpha to enhance the potential of immune checkpoint inhibitors in metastatic HNSCC.
European Commission Approves Enzalutamide in nmHSPC Subset
Those with high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer can now receive enzalutamide in the European Union.
European Commission Approves Cilta-cel in R/R Multiple Myeloma
Findings from the phase 3 CARTITUDE-4 trial support the European approval of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.
FDA Grants Breakthrough Therapy Status to Ziftomenib in R/R NPM1+ AML
Findings from the KOMET-001 trial support the breakthrough therapy designation for ziftomenib in NPM1-mutated acute myeloid leukemia.
Dostarlimab Earns FDA Priority Review in All Advanced Endometrial Cancers
The FDA has set a Prescription Drug User Fee Act date of August 23, 2024, for dostarlimab in all types of primary advanced endometrial cancer.
Addressing the Growing Colorectal Cancer Incidence in Younger Populations
Increasing screening for younger individuals who are at risk of colorectal cancer may help mitigate the rising early incidence of this disease.
Pembrolizumab Maintenance Yields Enduring Responses in HER2– Breast Cancer
Further research may validate identified biomarkers and refine patient selection criteria for pembrolizumab therapy in breast cancer.
FDA Approves Tovorafenib for Relapsed/Refractory Low-Grade Glioma
The FDA approval of the single-agent, oral pan-RAF inhibitor tovorafenib is based on efficacy results from the phase 2 FIREFLY-1 trial.
Alectinib Significantly Improves DFS Vs Chemo in Resected ALK+ NSCLC
Investigators of the phase 3 ALINA trial report no unexpected safety findings with alectinib in ALK-positive non–small cell lung cancer.
FDA Approves Lutetium Lu 177 Dotatate in Pediatric SSTR+ GEP-NETs
Data from 2 NETTER trials support lutetium Lu 177 dotatate's approval in somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Tislelizumab Earns European Approval in Non–Small Cell Lung Cancer
A series of phase 3 findings support the European approval of tislelizumab as a first-line and second-line treatment for non–small cell lung cancer.
ME-344/Bevacizumab Combo Shows Early Efficacy in mCRC
ME-344 and bevacizumab can now have an additional 20 patients enrolled on the phase 1b trial for relapsed metastatic colorectal cancer.
Laparoscopy Yields Increased Surgical Outcomes in Colorectal Cancer
Laparoscopy may reduce the degree of pain or length of hospital stay compared with open surgery for patients with colorectal cancer.
FDA Approves Nogapendekin Alfa-inbakicept/BCG in BCG-unresponsive NMIBC
Nogapendekin alfa-inbakicept is now approved for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer.
Questions Remain Around Neoadjuvant Chemoimmunotherapy in TNBC
Roshni Rao, MD, FACS, discussed the use of neoadjuvant chemoimmunotherapy and its complications in the treatment of patients with triple-negative breast cancer.
7-Gene Predictive Biosignature Helps Predict Ipsilateral Breast Cancer Recurrence
DCISionRT is a risk-assessment test for patients designed to predict RT benefit and develop their recurrence risk after surgery alone or with radiation.
Annamycin Earns European Orphan Drug Designation in Acute Myeloid Leukemia
Preliminary findings from the MB-106 trial support the potential benefit of annamycin/cytarabine in patients with acute myeloid leukemia.
Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery
Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.
Expert Highlights Applications of Proton Therapy in Radiation Oncology
The use of proton therapy may offer a more specific depth charge compared with conventional radiation, according to Timothy Chen, MD.
69 The Importance of Tri-Modality Therapy for De Novo Stage IV Invasive Lobular Carcinoma (ILC) Presenting With Bone-Only Metastases